InvestorsHub Logo
Followers 90
Posts 17382
Boards Moderated 0
Alias Born 09/06/2006

Re: pphmtoolong post# 251112

Sunday, 01/31/2016 1:41:56 PM

Sunday, January 31, 2016 1:41:56 PM

Post# of 345950

I do hope Peregrine can take another crack at pancreatic cancer. It is such a nasty disease.


The problem is that they would have to start over with an Abraxane combo. And that was a cost they did not see justified.

The Abraxane data was clearly good, despite Nuke's diss'ing of it. The 2 year survival (from his linked package insert) was 10% vs 6%. One can say that does not matter, but it is almost doubling ones chances of living 2 years (longer data was to thin to be meaningful).

[Nuke's survival numbers were math flawed. (N-E)/N is not even close to survival percent when the censor rate is high].

As a total aside, it might be a better target for BBs anyway. Pancreatic is surrounded by a very dense tissue (stroma) that makes penetration by drugs difficult. BB's are much smaller.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News